The Money Is Moving to the Layer Beneath the Molecule

TL;DR

Two major deals landed on the same day this week — Merck's $510M AI collaboration with Protillion Biosciences and Altaris's ~$375M take-private of Simulations Plus — both placing capital on the infrastructure beneath the molecule. Protillion's "lab-in-the-loop" platform generates its own wet-lab data to retrain its models; Simulations Plus has sold model-informed drug-development software for three decades. I think the pattern is clear: the smart money is betting that durable value in drug discovery sits in data generation and simulation tooling, not in the molecules themselves.

Merck signed a collaboration worth up to $510 million this week for AI that generates its own lab data. The same day, the PE firm Altaris took Simulations Plus private for about $375 million in cash.

Two deals, hours apart, both putting the money on the layer beneath the molecule.

Protillion Biosciences, Merck's new partner, runs a "lab-in-the-loop" platform: AI that produces its own experimental wet-lab data, then uses it to retrain and sharpen the models. Merck is paying for the engine that generates the data.

Simulations Plus, has sold model-informed drug-development software for three decades. Altaris, LLC paid $18.50 a share, a 26% premium, and plans to fold it into Chemical Computing Group, another modeling-software firm it already owns. Deliberate consolidation of the tooling layer.

One pharma major and one healthcare PE shop, on the same day, both investing in the same thing: the infrastructure that produces and interprets data.

For all the talk about AI molecules, you could argue the value keeps pooling one layer down. The models are only as good as the experimental data feeding them and the tooling that interprets it. That is the part most companies have underbuilt, and the part these buyers just paid up for.

AI has still not delivered a breakthrough molecule (even if we're getting closer...). But this week the smart money showed its hand on where the durable value will sit. Whoever owns the data generation and the simulation tooling owns the part that compounds.

Key takeaways

• Merck committed up to $510M to Protillion Biosciences for a "lab-in-the-loop" AI platform that generates its own experimental wet-lab data and uses it to retrain its models.
• Altaris paid a 26% premium to take Simulations Plus private for ~$375M, then plans to consolidate it with Chemical Computing Group — deliberate consolidation of the tooling layer.
• Both deals landed on the same day, with one pharma major and one healthcare PE shop independently betting on the same infrastructure thesis.
• The models are only as good as the experimental data feeding them and the tooling that interprets it — the part most companies have underbuilt.
• AI has still not delivered a breakthrough molecule, but the smart money this week showed its hand on where the durable value will sit.
• Whoever owns the data generation and the simulation tooling owns the part that compounds.